Carers and clinicians in todays NHS desire to use the very best advances in medical technology to provide consistently high clinical outcomes and the most safe and effective treatments for their patients. NHS Hospitals need to be as productive as possible to ensure that they are able to treat efficiently and cost effectively. Every day Medical Technology companies across the world are designing breakthrough innovative treatments who desire to introduce them to the NHS. The Device Access team have years of experience in brokering relationships between both. We start by thoroughly understanding the impact new treatments bring by analysing the existing care and treatment pathways, and only help companies that can provide real benefits to patients and the NHS system.
The National Institute for Health and Care Excellence (NICE) is recognised as the World’s Leading HTA. NICE provides national guidance and advice to improve health and social care. NICE guidance protects patients’ safety and supports people in the NHS so that it is possible for new treatments and tests to be introduced into the NHS in a responsible way. Many of the procedures that NICE investigates are new, but NICE also looks at more established procedures if there is uncertainty about their safety or how well they work.
Every year, the Device Access team assists credible Innovative Medical Technology providers successfully navigate NICE Medical Technology and Diagnostic evaluation programmes, leading to NHS adoption and diffusion of new breakthrough technologies for the benefits of its patients.
The National Institute for Health Research (NIHR) fund health and care research and translate discoveries into practical products, treatments, devices and procedures, involving patients, charities and the public in their work. The NIHR ensures the NHS is able to support the research of other funders to encourage broader investment in, and economic growth from health research, and helps keep the nation at the forefront of international research.
Device Access works collaboratively with the NIHR Office for Clinical Research Infrastructure (NOCRI), who support the life sciences industry navigate the NIHR infrastructure to form research partnerships and collaborations, to help bring new breakthrough treatments to patients faster.
The UK offers huge potential for innovative medical devices. Access a growing market with world-class resources, academic institutions and a clinical research infrastructure designed to prove concepts.
Despite a difficult economic climate in which other sectors have struggled, the UK Medical Technology sector has rapidly grown in recent years with an increase in turnover of 50% between 2009 and 2012.
Treating almost 1 million patients a day the NHS is a mature organisation with an established supply chain, and a strong appetite for clinical research and the adoption of medical innovations.
Treating almost 1 million patients a day the NHS is a mature organisation with an established supply chain and a strong appetite for proven innovation.
The potential is huge but navigating your way through the development pathway can be quite daunting. We have years of experience and insight plus access to realtime data that can really guide the way.
In December 2014, Device Access was granted a licence, to access NHS seudonymised Hospital Episode Statistics (HES) data, by NHS Digital.
Pseudonymised data takes the most identifying fields within a database and replaces them with artificial identifiers, unique number or pseudonyms, to reduce concerns over data protection and maintain patient confidentiality.
Device Access uses pseudonymised data for analytic purposes, to understand how new medical devices and diagnostic technologies will improve patient outcomes and NHS care pathways. All aggregated analysis, small numbers and outputs are supplied suppressed, as per NHS Digital’s strict HES Guidance.
We are governed and approved under the NHS Information and Governance (IG) toolkit and a member of the Information Commissioners Office (ICO) for Data Protection.
DAWN™ Trial Results Demonstrate a 73% Reduction in Disability in Stroke Patients Treated up to 24 Hours https://t.co/1YeB0gooDO
- Wednesday May 17 - 9:04pm
NIHR Diagnostic Evidence Co-operative Forum Oxford England 16-17 May 2017 https://t.co/jCSuKL0kvd
- Thursday Apr 20 - 3:32pm